防哮Ⅰ号方治疗儿童持续期哮喘临床研究

Clinical Study of Fangxiao Prescription Ⅰ Treatment of Chronic Persistent Asthma in Children

目的:观察防哮Ⅰ号方治疗儿童持续期哮喘的临床疗效。方法:将110例持续期哮喘患儿随机分为治疗组和对照组。治疗组给予防哮Ⅰ号方,对照组给予孟鲁司特钠咀嚼片。治疗4周后比较两组患儿临床疗效和中医证候复常率。结果:治疗组有效率为89.09%,对照组有效率为85.19%,两组有效率比较,差异无统计学意义(P>0.05);治疗组愈显率为70.91%,对照组愈显率为51.85%,两组愈显率比较,差异有统计学意义(P<0.05);治疗组各项中医证候复常率均优于对照组(P<0.05)。结论:防哮Ⅰ号方治疗儿童持续期哮喘疗效显著。

Objective： To observe the therapeutic effect of Fangxiao Prescription Ⅰ on asthma children at chronic duration stage.Methods： 110 cases were randomly divided into treatment group and control group with 55 cases in each group. The treatment group was given Fangxiao Prescription I,and the control group was given Montelukast Sodium Chewable Tablets. Evaluated the therapeutic effect after treatment of 4 weeks. Results： The effective rate of treatment group and the control group was 89. 09% and 85. 19%respectively,and there was no difference（ P〈0. 05）,the markedly effective rate of treatment group and the control group was70. 91% and 51. 85% respectively,and the difference was significant（ P〈0. 05）. The TCM syndrome in the treatment group were significantly improved（ P〈0. 05）. Conclusion： the therapeutic effect of Fangxiao Prescription Ⅰ on asthma children at chronic duration stage is significant.